From Investing.com: 2024-04-01 04:59:02

Vivos Therapeutics, a medical technology company, reported a decrease in total revenue for 2023 due to lower sales and enrollments. However, the company saw a reduction in operating expenses and net loss, with plans to become cash flow positive by the end of 2024. FDA clearance for their oral medical devices is expected to boost market demand.

Vivos anticipates new revenue streams and increased profitability in 2024, with expanding distribution channels and partnerships. Operating expenses are expected to continue decreasing, with a focus on cost-cutting initiatives. The company aims to reach cash flow breakeven with quarterly revenue between $6 million and $7 million.

While revenue from appliance sales and enrollments decreased in Q4 of 2023, the FDA clearance for OSA oral devices has generated increased interest in Vivos’ products. The company has made clinical breakthroughs and established partnerships to enhance distribution and revenue. Plans are in place to share regulatory approvals and initiatives throughout 2024.



Read more at Investing.com: Vivos Therapeutics aims for cash flow positivity in 2024 By Investing.com